ERBB2 and breast carcinoma: While clinical application of bortezomib has often been limited due to high toxicity clinical trials performed with carfilzomib showed a more favourable side effect profile [33], suggesting that carfilzomib might have the potential to improve treatment of HER2+/ER+ breast cancer patients.